Filings Don’t Lie: Lannett Co Inc: Flynn James E Opened Big New Position

Filings Don't Lie: Lannett Co Inc: Flynn James E Opened Big New Position

The New Flynn James E Holding in Lannett Co Inc

Flynn James E filed with the SEC SC 13G form for Lannett Co Inc. The form can be accessed here: 000119380516004217. As reported in Flynn James E’s form, the filler as of late owns 5.43% or 2,008,051 shares of the Health Care–company.

Lannett Co Inc stake is a new one for the and it was filed because of activity on November 8, 2016. We feel this shows Flynn James E’s positive view for the stock.

Lannett Co Inc Institutional Sentiment

Latest Security and Exchange filings show 241 investors own Lannett Co Inc. The institutional ownership in Q3 2015 is very high, at 71.16% of the outstanding shares. This is increased by 2898229 the total institutional shares. 26328076 were the shares owned by these institutional investors. In total 51 funds opened new Lannett Co Inc stakes, 93 increased stakes. There were 45 that closed positions and 73 reduced them.

Morgan Dempsey Capital Management Llc is an institutional investor bullish on Lannett Co Inc, owning 61540 shares as of Q3 2015 for 0.90% of its portfolio. Jw Asset Management Llc owns 31844 shares or 0.48% of its portfolio. K3 Parametrica Management Ltd have 1.85% of their stock portfolio for 7075 shares. Further, Gotham Asset Management Llc reported stake worth 0.57% of its US stock portfolio. The FL Zpr Investment Management owns 199675 shares. Lannett Co Inc is 10.12% of the manager’s US portfolio.

Business Profile

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.

Insitutional Activity: The institutional sentiment increased to 0.88 in 2016 Q2. Its up 0.07, from 0.81 in 2016Q1. The ratio increased, as 38 funds sold all Lannett Company, Inc. shares owned while 51 reduced positions. 27 funds bought stakes while 51 increased positions. They now own 27.61 million shares or 4.85% less from 29.01 million shares in 2016Q1.

Commonwealth Equity accumulated 0% or 11,531 shares. California State Teachers Retirement Systems has 58,101 shares for 0% of their US portfolio. Jpmorgan Chase And Co, a New York-based fund reported 265 shares. Next Finance Gru holds 300 shares or 0% of its portfolio. Deerfield Mngmt reported 895,591 shares or 0.84% of all its holdings. Orrstown Services Inc reported 30 shares or 0% of all its holdings. Teacher Retirement Of Texas has 4,101 shares for 0% of their US portfolio. Lsv Asset last reported 0.03% of its portfolio in the stock. Ameriprise Fincl reported 403,101 shares or 0.01% of all its holdings. Snow Mgmt L P has invested 0.7% of its portfolio in Lannett Company, Inc. (NYSE:LCI). Bb&T Corporation accumulated 40,831 shares or 0.02% of the stock. Federated Invsts Pa owns 45 shares or 0% of their US portfolio. Arizona State Retirement System has 0% invested in the company for 14,462 shares. Principal Financial Group Inc Inc, a Iowa-based fund reported 197,509 shares. Lpl Fincl Limited Liability Corporation has 0.01% invested in the company for 29,661 shares.

Insider Transactions: Since August 31, 2016, the stock had 0 insider buys, and 3 sales for $416,823 net activity. Another trade for 1,478 shares valued at $50,119 was sold by Maher James M.. On Thursday, September 15 the insider Landis G. Michael sold $139,988.

About 22,296 shares traded hands. Lannett Company, Inc. (NYSE:LCI) has risen 8.04% since April 8, 2016 and is uptrending. It has outperformed by 2.39% the S&P500.

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The company has a market cap of $896.85 million. The Firm makes and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. It currently has negative earnings. As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.

Lannett Company, Inc. (NYSE:LCI) Ratings Coverage

Out of 8 analysts covering Lannett (NYSE:LCI), 6 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 75% are positive. $70 is the highest target while $3 is the lowest. The $42.07 average target is 92.54% above today’s ($21.85) stock price. Lannett has been the topic of 20 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The rating was initiated by Susquehanna on Tuesday, July 21 with “Positive”. The stock has “Buy” rating given by TH Capital on Thursday, September 3. The firm has “Buy” rating by Roth Capital given on Friday, March 11. On Wednesday, June 29 the stock rating was initiated by Deutsche Bank with “Hold”. The stock of Lannett Company, Inc. (NYSE:LCI) earned “Buy” rating by Roth Capital on Thursday, March 24. The firm has “Hold” rating given on Thursday, November 5 by Craig Hallum. On Monday, September 7 the stock rating was upgraded by Zacks to “Strong-Buy”. On Thursday, March 24 the stock rating was downgraded by Canaccord Genuity to “Sell”. Craig Hallum maintained Lannett Company, Inc. (NYSE:LCI) on Thursday, August 27 with “Buy” rating. The rating was maintained by Roth Capital with “Buy” on Wednesday, August 26.

More notable recent Lannett Company, Inc. (NYSE:LCI) news were published by: Fool.com which released: “Why Lannett Company, Inc. Shares Got Pummeled Today” on October 17, 2016, also Businesswire.com with their article: “LANNETT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn …” published on November 08, 2016, Businesswire.com published: “IMPORTANT SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of …” on November 04, 2016. More interesting news about Lannett Company, Inc. (NYSE:LCI) were released by: Businesswire.com and their article: “Glancy Prongay & Murray LLP Commences Investigation on Behalf of Lannett …” published on November 03, 2016 as well as Prnewswire.com‘s news article titled: “SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of …” with publication date: November 04, 2016.

According to Zacks Investment Research, “Lannett, Inc. manufactures and distributes pharmaceutical products sold under generic names and historically has manufactured and distributed pharmaceutical products sold under its trade or brand names. In addition, the Company contract manufactures and private labels pharmaceutical products for other companies.”

LCI Company Profile

Lannett Company, Inc., incorporated on December 3, 1991, develops, makes, markets and distributes generic versions of brand pharmaceutical products. The Firm makes and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Firm has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment